Parker Institute for Cancer Immunotherapy shared a post on LinkedIn:
“New research from Stanford University School of Medicine describes a new approach to improving CAR T cell therapies.
Led by Crystal Mackall, Director of the PICI Center at Stanford Medicine, the study introduces a molecular ‘switch’ that helps engineered T cells regulate their activity, reducing exhaustion and enhancing antitumor responses in preclinical models. The findings show how leveraging the body’s natural biology may help create safer, more effective cell therapies for patients with cancer.”
Other articles about PICI on OncoDaily.